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Introduction: Radiography is an unreliable and insensitive tool for the assessment of structural lesions in the
sacroiliac joints (SIJ). Magnetic resonance imaging (MRI) detects a wider spectrum of structural lesions but has
undergone minimal validation in prospective studies. The Spondyloarthritis Research Consortium of Canada
(SPARCC) MRI Sacroiliac Joint (SIJ) Structural Score (SSS) assesses a spectrum of structural lesions (erosion, fat
metaplasia, backfill, ankylosis) and its potential to discriminate between therapies requires evaluation.
Methods: The SSS score assesses five consecutive coronal slices through the cartilaginous portion of the joint on
T1-weighted sequences starting from the transitional slice between cartilaginous and ligamentous portions of the
joint. Lesions are scored dichotomously (present/absent) in SIJ quadrants (fat metaplasia, erosion) or halves (backfill,
ankylosis). Two readers independently scored 147 pairs (baseline, 2 years) of scans from a prospective cohort of
patients with SpA who received either standard (n = 69) or tumor necrosis factor alpha (TNFα) inhibitor (n = 78)
therapy. Smallest detectable change (SDC) was calculated using analysis of variance (ANOVA), discrimination was
assessed using Guyatt’s effect size, and treatment group differences were assessed using t-tests and the
Mann–Whitney test. We identified baseline demographic and structural damage variables associated with change in
SSS score by univariate analysis and analyzed the effect of treatment by multivariate stepwise regression adjusted
for severity of baseline structural damage and demographic variables.
Results: A significant increase in mean SSS score for fat metaplasia (P = 0.017) and decrease in mean SSS score for
erosion (P = 0.017) was noted in anti-TNFα treated patients compared to those on standard therapy. Effect size for
this change in SSS fat metaplasia and erosion score was moderate (0.5 and 0.6, respectively). Treatment and
baseline SSS score for erosion were independently associated with change in SSS erosion score (β = 1.75, P = 0.003
and β = 0.40, P < 0.0001, respectively). Change in ASDAS (β = −0.46, P = 0.006), SPARCC MRI SIJ inflammation
(β = −0.077, P = 0.019), and baseline SSS score for fat metaplasia (β = 0.085, P = 0.034) were independently associated
with new fat metaplasia.
Conclusion: The SPARCC SSS method for assessment of structural lesions has discriminative capacity in demonstrating
significantly greater reduction in erosion and new fat metaplasia in patients receiving anti-TNFα therapy.* Correspondence: walter.maksymowych@ualberta.ca
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Radiography of the sacroiliac joint (SIJ) in axial spondy-
loarthritis (SpA) is a valuable diagnostic tool but is
unreliable and unresponsive for assessment of disease-
modifying treatment effects. There is therefore an un-
met need for imaging tools to assess the potential
disease-modifying effects of therapeutic agents early in
SpA when disease is still confined to the SIJ. Magnetic
resonance imaging (MRI) represents a substantial ad-
vance in the field due to its ability to visualize inflam-
mation in soft tissue as well as subchondral bone. This
is evident on fat-suppressed sequences such as short tau
inversion recovery. Recent MRI data also show that
resolution of inflammation may be associated with the
development of fat metaplasia on the T1-weighted spin
echo (T1WSE) sequence [1-3]. Fat metaplasia is not
observed on radiography and the histopathology of this
lesion is unknown, but it is frequently observed in SIJs
and at spinal locations that are also typical for inflam-
mation; that is, vertebral corners, adjacent to vertebral
endplates, facet and costo-vertebral joints [4]. We have
previously hypothesized that resolution of inflammation
in erosions is followed by development of a new tissue,
which on T1WSE MRI has the same signal intensity as
fat metaplasia [5]. We have called this type of lesion
backfill due to its appearance in the cavity of the ero-
sion, whereas the term fat metaplasia is used when this
lesion is located in the bone marrow.
There has been limited assessment of MRI-based
scores for structural lesions in the SIJ in clinical trials,
and little is known regarding the impact of different
therapies. One study has reported that scoring fat meta-
plasia may discriminate between therapies in a time
frame as short as 6 months [3]. However, the sig-
nificance of this for structural damage progression is
unclear. The Spondyloarthritis Research Consortium of
Canada (SPARCC) MRI Sacroiliac Joint Structural Score
(SSS) is a new scoring instrument that assesses a broader
spectrum of structural lesions in the SIJ, which include
erosion, fat metaplasia, backfill, and ankylosis [6]. Be-
cause of the increasing focus on effective treatment
intervention in early axial SpA, there is a need to vali-
date this new scoring instrument for its potential to dis-
criminate between therapies. The aim of this study was
to investigate whether there are differences in structural
progression on MRI in patients with axial SpA treated
with or without tumor necrosis factor-alpha (TNFα) in-
hibitor when assessed using the SPARCC MRI SSS.
Methods
Patients
We assessed scans from patients with available baseline
and 2-year MRI scans and meeting the modified New York
criteria [7] recruited in a consecutive manner to aprospective cohort. Patients are recruited from commu-
nity-based clinical practice and academic-based outpatient
facilities in the city of Edmonton irrespective of what treat-
ment they have received. Baseline and 2-year MRI scans
were available for 147 patients with axial SpA meeting the
modified New York criteria [7], who had been evaluated
systematically according to a standardized protocol. Of
these, 68 patients received standard therapies (nonsteroi-
dal anti-inflammatory agents and/or physiotherapy) and
79 patients initiated TNFα inhibitor therapy. In addition
to demographic variables, the Assessments in Spondyloar-
thritis International Society core set is used to assess signs
and symptoms of disease activity [8], and C-reactive pro-
tein (CRP) (mg/L) and the SPARCC MRI SIJ inflammation
scores are used to objectively assess degree of inflamma-
tion [9]. Assessments are conducted at baseline, at 3 to 6
months for patients starting TNFα inhibitor, and annually
for all patients as described previously [10]. SPARCC MRI
SIJ inflammation scores are recorded for each patient in
the cohort by a reader unconnected with this study.
Study approval
The study received ethical approval from the Health Re-
search Ethics board of the University of Alberta and was
performed in accordance with the Helsinki Declaration.
Written informed consent was obtained from all study
participants before inclusion into the observational cohort.
Magnetic resonance imaging protocol
Scans were semi-coronal T1WSE sequences of the SIJs.
The scan parameters were as follows: 15 to 19 slices, 4
mm slice thickness, 0.4 mm interslice gap, field of view
280 to 300 mm, repetition time 423 to 450 milliseconds,
echo time 12 to 13 milliseconds, echo train length 3,
and matrix 512 × 256 pixels. Although scans from all
patients included the short tau inversion recovery se-
quence, these scans were deleted from the set of scans
included in this validation process to avoid simulta-
neously eliciting information on inflammation provided
by this sequence.
Structural lesion definitions
We adopted the following standardized definitions of
structural lesions of the SIJ on MRI, which were deve-
loped by the Canada–Denmark MRI Working Group [4]
and which were extended in a subsequent report to in-
clude backfill [5].
Fat metaplasia is defined as an increased signal on
T1WSE. The reference for normal bone marrow signal
is the marrow signal in the center of the sacrum at the
corresponding craniocaudal level. In order to be scored
in the SSS method, the lesion has to demonstrate a
homogeneous bright signal that is at least 1 cm in depth
from the joint surface.
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dark appearance of either the iliac or sacral cortical bone
at its anticipated location and loss of the normal bright
appearance of adjacent bone marrow on T1WSE.
Backfill is defined as complete loss of iliac or sacral
cortical bone at its anticipated location and an increased
signal on T1WSE that is clearly demarcated from adja-
cent normal marrow by irregular dark signal reflecting
sclerosis.
Finally, ankylosis is defined as a bone marrow signal
on T1WSE extending between the sacral and iliac bone
marrow.
Examples of structural lesions together with a module
describing the SSS method and a reference image set
based on Digital Imaging and Communications in
Medicine images are available online [11]. This training
module also includes a schematic of the SIJ for direct
electronic data entry online and raw scores from two
reader pairs who achieved the highest reliability in the
validation exercises (vide infra) to facilitate calibration of
nonexpert readers. Bone sclerosis and abnormalities of
the synovial cavity are not addressed in the SSS method
because of poor reproducibility in previous reading
exercises.
Scoring methodology
The SPARCC SSS method incorporates key scoring prin-
ciples from the SPARCC SIJ inflammation score, which
is based on assessment of consecutive slices through the
SIJ, division of each SIJ into quadrants, and dichotomous
(present/absent) scoring of lesions in each quadrant.
Evaluation of structural lesions in the SIJ using the SSS
method is conducted using T1WSE scans and proceeds
sequentially in the following steps.
First, the transitional slice is identified by scrolling
through the Digital Imaging and Communications in
Medicine images from anterior to posterior semi-coronal
slices through the joint. The transitional slice is defined as
the first slice in the cartilaginous portion that has a visible
portion of the ligamentous joint when viewed from anter-
ior to posterior.
All time points are then anatomically matched accor-
ding to the transitional semi-coronal SIJ slice. The link
function on Digital Imaging and Communications in
Medicine software allows simultaneous scrolling of ana-
tomically matched images from the transitional slice an-
teriorly, thereby facilitating detection of change in lesions
between time points.
Finally, five consecutive semi-coronal slices are assessed
starting from the transitional slice and scrolling anteriorly.
The SIJ cavity together with adjacent bone marrow should
still be clearly visible at the most anterior slice.
The presence/absence of lesions is scored in SIJ quad-
rants (fat, erosion) or halves (backfill, ankylosis) using adirect online data-entry system based on a schematic of
the SIJ. Scoring ranges are: fat metaplasia (0 to 40), ero-
sion (0 to 40), backfill (0 to 20), ankylosis (0 to 20).Reading exercises
Reads were conducted blinded to patient demographics
and treatment. We first conducted a calibration exercise
of 20 cases randomly selected from the cohort with
baseline and 2-year scans that were scored by two
readers blinded to time point. In the primary exercise,
two readers independently scored the 147 cases with
baseline and 2-year scans blinded to time point. Data
were directly entered online into a web-based scoring
system that is illustrated as a schematic with each SIJ di-
vided into quadrants.Statistical analysis
We used descriptive statistics to compare the clinical
characteristics and the number (percentage) of patients
with any change and the mean (standard deviation)
change in each of the four structural lesion scores for the
two treatment groups. Analyses were performed using the
mean scores of the two readers. Comparisons of propor-
tions of patients demonstrating any change in SSS were
conducted using Fisher’s exact test. Treatment group dif-
ferences were assessed using cumulative probability plots,
unpaired t tests, and the Mann–Whitney test for nonpara-
metric data. Correlations were analyzed using Spearman’s
rho between: change in objective (CRP, SPARCC MRI SIJ
inflammation score) and other (Ankylosing Spondylitis
Disease Activity Score (ASDAS)) measures of inflamma-
tion; change in MRI SSS for fat metaplasia, erosion, and
backfill; and change in MRI SSS for ankylosis.
If treatment group differences for change in specific
structural lesion scores were significant in group ana-
lyses, we explored the potential impact of baseline diffe-
rences between treatment groups on change in MRI SSS
by analyzing variables related to demographics (gender,
B27 status) and disease severity (SSS for erosion, fat
metaplasia, backfill, ankylosis) using univariate regres-
sion, with a significant interaction defined as P ≤ 0.10.
We then analyzed interaction effects between treatment
and these variables.
The effect of treatment on change in SSS was further
analyzed in multivariate stepwise regression analyses
that included the following variables: age, sex, symptom
duration, baseline and 2-year change in ASDAS, base-
line and 2-year change in CRP, baseline and 2-year
change in SPARCC SIJ inflammation score, and baseline
SSS for erosion, fat metaplasia, backfill, and ankylosis.
Significant interactions were further analyzed by inclu-
ding the interaction terms in multivariate stepwise re-
gression analyses.
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using the Bland-Altman 80% levels of agreement and
expressed as an absolute value and as a percentage of
the maximum score [12]. The SDC provides an absolute
measure of agreement, which can be used as a guideline
for the clinicians and applied clinically for assessing real
change beyond measurement error at the individual pa-
tient level. Discrimination was assessed using Guyatt’s
effect size, which was calculated by dividing the mean of
the change scores in the TNFα inhibitor group by the
standard deviation of the change scores in the standard
therapy group for each of the structural lesions. Effect
sizes of at least 0.2, 0.5, and 0.8 are considered small,
moderate, and large, respectively.
Results
Baseline characteristics
Demographic and disease characteristics at baseline
showed significantly more active disease (Bath Ankylosing
Spondylitis Disease Activity Index, total back pain, noctur-
nal back pain, patient global, ASDAS, CRP) (P <0.0001 for
all variables) in patients who received TNFα inhibitor
therapy (Table 1). Functional severity (Bath Ankylosing
Spondylitis Functional Index [13]) and radiographic seve-
rity (modified Stoke Ankylosing Spondylitis Spine Score
[14]) were also worse in those who received TNFα inhibi-
tor therapy (P < 0.0001 for both variables). Significantly
more ankylosis was recorded in the SIJ on the baselineTable 1 Baseline demographics and disease status in 147
patients with axial spondyloarthritis receiving either






Age 40.44 (12.86) 40.29 (10.70)
Males No (%) 47 (69%) 64 (81%)
Symptom duration 16.12 (10.62) 16.94 (9.64)
BASDAI 3.71 (2.24) 5.99 (2.12)
Total back pain 3.69 (2.67) 5.75 (2.57)
Nocturnal back pain 4.03 (2.75) 6.05 (2.60)
Patient global score 3.85 (2.57) 5.91 (2.84)
BASFI 2.36 (2.56) 4.83 (2.71)
HLA B27a 55 (87%) 58 (85%)
C-reactive protein 6.83 (9.53) 18.37 (18.84)
ASDAS 2.29 (1.02) 3.55 (1.10)
mSASSS 12.32 (18.15) 17.47 (19.08)
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing
Spondylitis Disease Activity Index [15]; BASFI, Bath Ankylosing Spondylitis
Functional Index [13]; HLA, human leukocyte antigen; mSASSS, modified Stoke
Ankylosing Spondylitis Spine Score [14]; NSAID, nonsteroidal anti-inflammatory
drug; TNFα, tumor necrosis factor alpha. Values represent mean (standard
deviation) or number (percentage). aMissing values in 5 and 11 patients of the
standard therapy and TNFα inhibitor groups, respectively.MRI scan in patients who received TNFα inhibitor
therapy (P = 0.02) (Table 2).
Detection of change in SPARCC MRI SSS
The SDC was comparable for structural lesion scores at
5 to 7% of the scoring range although higher for backfill
at 14% of the scoring range (Table 2). The number (per-
centage) of patients with change > SDC for the standard
therapy and TNFα inhibitor groups was five (7.4%) and
15 (19%) patients for fat metaplasia, eight (11.8%) and
15 (19%) patients for Backfill, 12 (17.6%) and 24 (30.4%)
patients for erosion, and seven (10.3%) and 11 (13.9%)
patients for Ankylosis, respectively. A significant in-
crease in mean SSS for fat metaplasia (P = 0.017) and a
decrease in mean SSS for erosion (P = 0.017) was noted
in TNFα inhibitor-treated patients compared with those
on standard therapy. The effect size for the change in
SSS fat metaplasia and erosion score in the TNFα inhibi-
tor versus standard therapy groups was moderate (0.5
and 0.6, respectively). There was a significantly higher
percentage of patients who developed new fat metaplasia
on TNFα inhibitor therapy (38.0%) versus those who re-
ceived standard therapy (17.6%) (P = 0.01), while more
patients on standard therapy had a decrease in fat meta-
plasia compared with those on TNFα inhibitor therapy
(32.3% vs. 19.0%, respectively) (Figure 1). Significantly
more patients on standard therapy developed new ero-
sion compared with those on TNFα inhibitor therapy
(26.5% vs. 13.9%, respectively, P = 0.037) (Figure 1).
These differences between treatment groups are further
evident on the cumulative probability plots (Figure 2).
Correlations between change in SPARCC MRI SSS
Significant correlation was noted between 2-year change in
SPARCC MRI SIJ inflammation score and change in SSS
for erosion in patients in both treatment groups (r = 0.29
(P = 0.032) and r = 0.49 (P < 0.0001) for standard therapy
and TNFα inhibitor groups, respectively) (Table 3). There
was a significant inverse correlation between change in
SPARCC MRI SIJ inflammation score and change in CRP
with change in SSS for fat metaplasia in patients on TNFα
inhibitor therapy (r = −0.40 (P = 0.001) and r = −0.27
(P = 0.023), respectively). There was no significant cor-
relation between change in CRP and change in SSS for fat
metaplasia in the standard therapy group. The correlation
between SPARCC MRI SIJ inflammation score and fat
metaplasia was significant in the standard therapy group
(r = −0.28 (P = 0.041)) but this was weaker compared with
the TNFα inhibitor group. Decreased SSS for erosion cor-
related strongly with increased SSS for fat metaplasia in
TNFα inhibitor-treated patients (r = −0.54 (P < 0.0001))
but not in standard therapy-treated patients. Decreased
SSS for erosion correlated significantly with increased SSS
for ankylosis in both treatment groups (r = −0.33
Table 2 Detection of change in SPARCC MRI SSS and discrimination of the SSS in 147 patients with axial








Anti-TNFαa Standardb Anti-TNFαa Standardb
Fat metaplasia 2.2 (5.5%) 3.6 (5.1) 4.0 (6.6) NS 0.7 (2.2) 0.2 (1.5) 0.5 0.017
Backfill 2.8 (14%) 3.7 (4.5) 2.2 (3.1) 0.08 0.1 (2.9) 0.4 (1.9) 0.03 NS
Erosion 3.05 (7.6%) 2.7 (3.2) 3.6 (4.4) NS −1.5 (2.8) −0.5 (2.7) 0.6 0.017
Ankylosis 1.39 (7%) 7.3 (8.5) 4.1 (7.0) 0.02 0.4 (1.6) 0.3 (1.2) 0.3 NS
MRI, magnetic resonance imaging; NS, not significant; SD, standard deviation; SDC, smallest detectable change; SPARCC, Spondyloarthritis Research Consortium of
Canada; SSS, Sacroiliac Joint Structural Score; TNFα, tumor necrosis factor alpha. aPatients receiving TNFα inhibitor therapy (n = 79). bPatients receiving standard
therapy (nonsteroidal anti-inflammatory drug and/or physiotherapy, n = 68).
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apy and TNFα inhibitor groups, respectively). Increase in
SSS for fat metaplasia correlated significantly with in-
creased SSS for ankylosis in TNFα inhibitor-treated pa-




Neither gender nor B27 status was associated with change
in erosion. For disease activity measures, the baseline
ASDAS (β = −0.40, P = 0.052) and baseline and 2-year
change in SPARCC MRI SIJ inflammation score (β = −0.12,
P = 0.002 and β = 0.17, P < 0.0001, respectively) were as-
sociated with change in erosion. For structural damage
parameters, the baseline SSS for ankylosis (β = 0.088,
P = 0.002) and baseline SSS for erosion (β = −0.39,
P < 0.0001) were associated with change in erosion. Sig-
nificant interaction between baseline variables and treat-
ment for change in erosion was only evident for baseline
SSS for erosion.
Change in fat metaplasia
Neither gender nor B27 status was associated with
change in fat metaplasia. For disease activity measures,Figure 1 Patients with axial spondyloarthritis demonstrating any cha
fat metaplasia or erosion. Percentage of patients with axial spondyloarthriti
Research Consortium of Canada magnetic resonance imaging Sacroiliac Joint S
standard therapy (nonsteroidal anti-inflammatory drug and/or physiotherapy, nthe baseline and 2-year change in ASDAS (β = −0.36,
P = 0.009 and β = −0.36, P = 0.009, respectively), the
baseline and 2-year change in CRP (β = 0.025, P = 0.014
and β = −0.027, P = 0.006, respectively), and the baseline
and 2-year change in SPARCC MRI SIJ inflammation
score (β = 0.059, P = 0.019 and β = −0.08, P = 0.005,
respectively) were associated with change in fat metapla-
sia. For baseline structural damage parameters, the SSS
for backfill (β = 0.076, P = 0.057), SSS for erosion
(β = 0.11, P = 0.006), and SSS for fat metaplasia
(β = 0.06, P = 0.025) were associated with change in fat
metaplasia. There were no significant interactions bet-
ween baseline variables and treatment for change in fat
metaplasia.
Multivariate analyses
Because treatment group differences for change in fat
metaplasia SSS and erosion SSS were significant, the ef-
fect of treatment on change in these scores was further
analyzed in multivariate stepwise regression that in-
cluded demographic variables as well as the variables
that were significant (P < 0.10) in univariate analysis.
Significant variables independently associated with
change in SSS for erosion were treatment, 2-year change
in SPARCC SIJ inflammation score, and baseline SSS fornge (increase or decrease) in Sacroiliac Joint Structural Scores for
s who demonstrate any change (increase or decrease) in Spondyloarthritis
tructural Scores for fat metaplasia or erosion after 2 years on either
= 68) or tumor necrosis factor alpha (TNFα) inhibitor therapy (n = 79).
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Figure 2 Two-year change in mean Sacroiliac Joint Structural Scores for fat metaplasia and erosion in patients with axial
spondyloarthritis. Cumulative probability plots illustrating 2-year change in mean Spondyloarthritis Research Consortium of Canada magnetic
resonance imaging Sacroiliac Joint Structural Scores for (A) fat metaplasia and (B) erosion in patients with axial spondyloarthritis on standard
therapy (nonsteroidal anti-inflammatory drug and/or physiotherapy, n = 68) and tumor necrosis factor alpha (TNFα) inhibitor (n = 79) therapy.
Tx, therapy.
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between either treatment and gender or treatment and
B27 in regression analyses addressing change in erosion.
A significant interaction was observed for treatment and
baseline SSS for erosion (β = −0.46, P < 0.0001) but not
for other baseline SSS. The difference in erosion change
scores between the standard and anti-TNFα groups with
the same baseline score depends on the baseline SSS for
erosion. The higher the baseline SSS for erosion, the
greater the expected difference in SSS erosion change
scores between the standard and anti-TNFα groups
(Figure S1 in Additional file 1). Addition of the inter-
action term treatment/baseline SSS for erosion to the
regression model that included all of the variables cited
in Table 4 increased the explained variance in the
dependent variable and the adjusted R2 from 0.44 to
0.52.
Significant variables independently associated with
change in SSS for fat metaplasia were 2-year change in
ASDAS, 2-year change in SPARCC MRI SIJ inflamma-
tion score, and baseline SSS for fat metaplasia (Table 5).No significant interaction was evident between treat-
ment and gender, between treatment and B27, or bet-
ween treatment and baseline SSS in regression analyses
addressing change in fat metaplasia (data not shown).
Discussion
We have developed a scoring method for structural le-
sions in the SIJs, which is based on the same scoring
principles used in the SPARCC MRI SIJ inflammation
scoring method. The approach to the selection of MRI
slices is anatomically defined, the majority of the car-
tilaginous portion of the joint is assessed on consecutive
slices in the semi-coronal plane, lesions are scored in SIJ
quadrants, and scoring is dichotomous (present/absent),
which simplifies assessment and improves reliability.
The pathological abnormalities visible on MRI often in-
clude mixed lesions with complex anatomical appea-
rances, which may challenge scoring approaches based
on estimates for percent volume of the SIJ quadrant.
This analysis was aimed at generating preliminary data
on discrimination and showed that the SSS method
Table 3 Correlation matrix demonstrating associations between changes in inflammatory parameters and structural lesions on MRI in patients with axial
spondyloarthritis receiving either standard or TNFα inhibitor therapy
TNFα inhibitor therapy (n = 79) Standard therapy (n = 68)
CRP ASDAS SPARCC MRI SIJ inflammation score SSS for fat metaplasia SSS for erosion SSS for backfill SSS for ankylosis
CRP 0.27, P = 0.05 0.19, P = 0.NS 0.13, P = 0.NS 0.16, P = NS −0.03, P = NS −0.19, P = NS
ASDAS 0.27, P = 0.042 0.15, P = NS −0.04, P = NS 0.20, P = NS −0.12, P = NS −0.23, P = NS
SPARCC MRI SIJ inflammation score 0.12, P = NS 0.12, P = NS −0.28, P = 0.041 0.29, P = 0.032 −0.34, P = 0.011 −0.02, P = NS
SSS for fat metaplasia −0.27, P = 0.023 −0.07, P = NS −0.40, P = 0.001 −0.08, P = NS 0.31, P = 0.0097 0.21, P = 0.092
SSS for erosion 0.023, P = NS −0.23, P = NS 0.49, P < 0.0001 −0.54, P < 0.0001 −0.39, P = 0.0011 −0.33, P = 0.0058
SSS for backfill −0.11, P = NS 0.04, P = NS −0.39, P = 0.001 0.30, P = 0.008 −0.46 < 0.0001 −0.02, P = NS
SSS for ankylosis 0.10, P = NS 0.07, P = NS −0.09, P = NS 0.35, P = 0.0018 −0.33, P = 0.0027 0.06, P = NS
Data presented as Spearman’s rho and P values. Data in bold are statistically significant. ASDAS, Ankylosing Spondylitis Disease Activity Score; CRP, C-reactive protein; MRI, magnetic resonance imaging; NS, not















Table 4 Multivariate stepwise regression analyses of data from 147 patients with axial spondyloarthritis followed over
2 years assessing the associations between treatment and development of erosion or fat metaplasia
β coefficient SE t value P value
TNFα inhibitor treatment −1.33 0.47 −3.0 0.003
2 year change in SPARCC SIJ inflammation score 0.09 0.036 2.57 0.012
Baseline SSS erosion score −0.40 0.059 −7.1 <0.0001
Dependent variable: 2-year change in SSS for erosion. Adjusted R2 = 0.45. Variables not included in the model: age, sex, symptom duration, baseline Ankylosing
Spondylitis Disease Activity Score, baseline SPARCC SIJ inflammation score, and baseline SSS for ankylosis. SE, standard error; SIJ, sacroiliac joint; SPARCC,
Spondyloarthritis Research Consortium of Canada; SSS, Sacroiliac Joint Structural Score; TNFα, tumor necrosis factor alpha.
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of change over 2 years between patients on standard and
TNFα inhibitor therapies. The latter group demonstrated
a significantly higher increase in SSS for fat metaplasia as
well as significantly greater decrease in SSS for erosion
compared with patients on standard therapy. Our data
support the hypothesis that resolution of inflammation is
associated with reduction in erosion and development of
fat metaplasia and that this is more likely to occur follo-
wing treatment with TNFα inhibitors.
There has been limited study aimed at development
and validation of structural lesions in the SIJs using
MRI. Erosion has been quantified according to a grading
scheme based on the number of erosions per SIJ (1 = 1
to 2 erosions per SIJ, 2 = 3 to 5 erosions per SIJ, 3 = >5
erosions per SIJ) [3]. Reliability for status score was very
good but data for change scores were not reported. In a
second method, erosion was graded in both cartilaginous
and ligamentous compartments and severity was graded
according to the extent of subcortical bone affected
(0 = no erosion, 1 = <25% erosion, 2 = 25 to 50% ero-
sion, 3 = >50% erosion) [16]. Reliability for status score
was good but data for change scores were not reported.
Assessment of erosion in the ligamentous compartment
may be challenging due to the presence of normal liga-
mentary insertions associated with irregularity of cortical
bone that may simulate the appearance of erosion. The
complex anatomy of the joint together with the frequent
finding of complex patterns of structural lesions that
occur in combination on the same MRI slices may also
challenge reliable estimation of extent of involvement
that is based on number of erosions per joint or percent
of subcortical bone affected.Table 5 Multivariate stepwise regression analyses of data fro
2 years assessing the associations between treatment and de
β coefficie
2 year change in ASDAS −0.43
2 year change in SPARCC SIJ inflammation score −0.077
Baseline SSS score for fat metaplasia 0.085
Dependent variable: 2-year change in SSS for fat metaplasia. Adjusted R2 = 0.18. Va
baseline ASDAS, baseline and 2-year change in C-reactive protein, baseline SPARCC
ASDAS, Ankylosing Spondylitis Disease Activity Score; SE, standard error; SIJ, sacroilia
sacroiliac joint structural score.Our observations indicate that the morphology of ero-
sion may change as inflammation resolves. We have de-
fined erosion as a full thickness breach of cortical bone
together with loss of the adjacent bright marrow signal
on T1WSE scans, indicating replacement of normal fatty
marrow by inflammatory tissue. We previously hypothe-
sized that resolution of inflammation is associated with
sclerosis at the edge of the resorbed cavity and infilling
of the cavity with tissue that demonstrates an increased
signal on T1WSE MRI consistent with fat metaplasia
[5]. Backfill is the term we gave to this appearance of
new tissue with high signal on T1WSE MRI that is
clearly demarcated from adjacent marrow by an irregular
dark signal reflecting sclerosis (Figure three in [5]). This
evolution of erosion to backfill was evident in one-third
of patients in this study cohort after 2 years of follow up,
and correlation analysis demonstrated a significant asso-
ciation with resolution of inflammation irrespective of
treatment. The complex morphology of backfill requires
more calibration than other structural lesions in the SIJ,
as shown by the higher relative cutoff value for SDC.
Several reports have shown that fat metaplasia occurs
following resolution of inflammation in SpA and several
scoring methods have been developed, although none as
yet has been validated to show that change scores can be
reliably detected. One report assessed fat lesions dichot-
omously (present/absent) according to SIJ quadrants and
a 0 to 8 scoring range based on a global evaluation of
the SIJ rather than scoring of SIJ quadrants in individual
slices [3]. Development of new lesions correlated with
resolution of inflammation and a significant difference
was noted between patients on etanercept versus those
on salazopyrine as soon as 24 weeks. Reliability form 147 patients with axial spondyloarthritis followed over
velopment of erosion or fat metaplasia




riables not included in the model: age, sex, symptom duration, treatment,
SIJ inflammation score, baseline SSS for backfill, and baseline SSS for erosion.
c joint; SPARCC, Spondyloarthritis Research Consortium of Canada; SSS,
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were not reported. Nevertheless, these data are con-
sistent with our data and show that assessment of fat
metaplasia may be discriminatory, especially in compari-
sons that include patients on TNFα inhibitor therapy. A
second method grades fat metaplasia in both cartila-
ginous and ligamentous compartments and grades seve-
rity according to the extent of subcortical bone affected
(0 = no fat, 1 = <25% fat, 2 = 25 to 50% fat, 3 = >50%
fat) [16]. A weighting of 1 is added for fat metaplasia ex-
tending ≥1 cm beneath the joint surface. This method
has only been validated for reliability of status score,
which was reported as good. A limitation of this ap-
proach is that fat metaplasia may also occur beyond the
subcortical region and its presence in a subcortical re-
gion may be less specific for SpA [17].
The primary study limitation is that the data are derived
from an observational cohort and not from randomized
groups so that patients receiving TNFα inhibitors had
more severe disease at baseline. In particular, change in
any structural damage parameter may reflect the pos-
sibility that there are more severe structural changes at
baseline in the TNFα inhibitor group due to confounding
by indication. Such patients may therefore be more likely
to show further structural changes over time, which may
not reflect a treatment effect but a more severe disease
phenotype. Multivariate analysis adjusted for extent of
structural damage at baseline and demographic variables
showed that reduction in inflammation, defined by de-
creased SPARCC MRI SSS for inflammation, and category
of treatment were both independently associated with re-
duction in erosion score. Change in erosion also depended
on the extent of erosion at baseline as defined by the SSS
for erosion but there was evidence of a significant inter-
action with treatment. The most probable interpretation
of this finding is that the observed reduction in erosion is
more likely in the TNFα inhibitor group the greater the
extent of erosion at the start of therapy, and this is asso-
ciated with its anti-inflammatory effect. Category of treat-
ment did not emerge as a significantly associated variable
in multivariate analysis of change in fat metaplasia ad-
justed for structural damage at baseline and demographic
variables. Change in measures of inflammation (ASDAS,
SPARCC MRI SIJ inflammation score) and baseline SSS
for fat metaplasia were independently associated with
2-year change in fat metaplasia, suggesting that the
likelihood of developing fat metaplasia may be more
strongly associated with a particular phenotype of disease
rather than a specific treatment.
A second major limitation of this study is that MRI
assessments were conducted 2 years apart and it is
necessary to demonstrate whether change in structural
lesions can be reliably demonstrated within shorter time
frames that may allow the conduct of randomizedstudies with feasible sample sizes. Lesion characteristics
need to be further defined through comparative studies
using computed tomography, and their prognostic sig-
nificance should be analyzed to determine whether they
could be useful surrogate endpoints in trials of disease-
modifying therapies.
Conclusions
We have tested the discriminative metrics of a new scor-
ing methodology for the assessment of structural lesions
on MRI in the SIJ of patients with SpA that is based on
the same principles as the widely used SPARCC MRI SIJ
inflammation score. We show greater fat metaplasia and
less erosion over 2 years in patients receiving TNFα in-
hibitors compared with those on standard therapy. Our
prospective data support the hypothesis that both reso-
lution of erosion and development of new fat metaplasia
are associated with the resolution of inflammation. How-
ever, development of new fat metaplasia may also be
more directly associated with a particular phenotype of
disease rather than the use of any specific therapeutic
agent. Further validation for discriminatory capacity over
shorter time frames and for prognostic significance is
warranted.
Additional file
Additional file 1: Figure S1. Depicting predicted erosion change
scores for regression equation without baseline SSS for erosion/treatment
interaction. The lines are parallel but the intercepts are different.
Regardless of the SSS for baseline erosion, the predicted difference in
erosion change scores between the treatment group and standard group
with the same baseline erosion SSS is −1.32.
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